Clinical Trial Results Home

Prevention of Coronary Artery Disease and Lipid Lowering

 Contents
Summary Slides
Inflammation
CETP
LDL Lowering
HDL Raising
Other Lipid Lowering
Obesity
Smoking Cessation
Vitamins
 Summary Slides

ATP 3: Adult Treatment Panel III

      -Implications of Recent Clinical Trials for the National Cholesterol Education Program ATP III Guidelines by Dr. Scott M. Grundy

CHAMP: Cardiac Hospitalization Atherosclerosis Management Program

      -Rationale and Design by Dr. Gregg C. Fonarow and Dr. Anna Gawlinski (2000)

Cholesterol Metabolism

      -Overview

EPIC-Norfolk: European Prospective Investigation of Cancer

      -Value of Lipoprotein Particle Number and Size as Predictors of Coronary Artery Disease in Apparently Healthy Men and Women by Dr. Karim El Harchaoui (2007)

FIT HEART: A Novel Family-based Intervention Trial to Improve Heart Health

      -Trial Results by Dr. Lori Mosca

HDL: High Density Lipoprotein

      -Overview by Dr. Peter Libby

HDL or LDL

      -Which is More Important? by Dr. Christopher P. Cannon (2000)

HMG Reductase Inhibitors

      -Meta-analysis of the Impact of HMG Reductase Inhibitors on Clinical Events

Lipid Management Advances

      -Overview of The National Cholesterol Education Program (NCEP), National Health and Nutrition Examination Survery (NHANES-III), and Lipid Treatment Assessment Project (L-TAP)

PIOSTAT: Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein

      -Trial Overview by Dr. Markolf Hanefeld (2007)

 

RESPONSE: Randomized Evaluation of Secondary Prevention by Outpatient Nurse Specialists

      -Trial Results by Dr. Ron JG Peters (ESC 2010)

Statin Therapy

      -The Benefit of Statin Therapy Before and After Coronary Revascularization by Dr. C. Michael Gibson

(Return to Contents)

 Inflammation

ARISE: Aggressive Reduction of Inflammation Stops Events

      -Study Overview by Dr. Jean-Claude Tardif (ACC 2007)

MEDAL Program: Multinational Etoricoxib and Diclofenac Arthritis Long-term

      -Cardiovascular Risk with COX-IIs - MEDAL Program by Dr. Christopher P. Cannon

(Return to Contents)

 CETP

Dal-OUTCOMES: Effects of the Cholesteryl Ester Transfer Protein Inhibitor Dalcetrapib in Patients with Recent Acute Coronary Syndrome

      -Trial Overview by Dr. Gregory G. Schwartz (AHA 2012)

 

DEFINE: Determining the Efficacy of Tolerability of CETP Inhibition With Anacetrapib

      -Trial Results by Dr. Christopher Cannon (AHA 2010)

ILLUSTRATE: Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation

      -Trial Overview by Dr. Steven E. Nissen (ACC 2007)

 

Lipid-Modulating Effects of Evacetrapib, a Novel CETP Inhibitor, Administered as Monotherapy or in Combination with the Most Commonly Used Statins:

      -Trial Overview by Dr. Stephen Nicholls (AHA 2011)

 

(Return to Contents)

 LDL Lowering

4S: Scandinavian Simvastatin Survival Study

      -Diabetes by Dr. SM Haffner

      -Elderly and Women by Dr. Tatu A. Miettinen

      -Simvastatin vs Placebo for Mortality in Coronary Heart Disease

      -Stroke by Dr. Terje R. Pedersen

A to Z: Aggrastat to Zocor

      -Aggrastat-Phase of the A to Z Trial (ACC 2003)

ACTIVATE: Acyl-coenzyme A: Cholesterol Acyltransferase (ACAT) Inhibition on the Progression of Coronary Atherosclerosis

      -Trial Overview by Dr. Steven E. Nissen (AHA 2005)

AFCAPS/TexCAPS: Air Force Texas Coronary Atherosclerosis Prevention Study

      -Results of AFCAPS/TexCAPS by Dr. John R. Downs, et al.

ALLHAT - LLT: Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

      -Trial Overview

ARBITER-2: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 Trial

      -Trial Overview by Dr. A. Taylor (AHA 2004)

ARMYDA-ACS: Atorvastatin for Reduction of Myocardial Damage During Angioplasty — Acute Coronary Syndromes

      -Trial Overview by Dr. Germano Di Sciascio

ASTEROID: A Study To Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden

      -Trial Overview by Dr. Steven E. Nissen (ACC 2006)

AVERT: Atorvastatin Versus Revascularization Treatments

      -Trial Overview by Dr. Bertram Pitt (AHA 1998)

CARE: Cholesterol And Recurrent Events

      -The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels by Dr. Frank M. Sacks, et al.

GAUSS: Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects

      -Interim Results by Dr. Evan Stein et al. (AHA 2012)

IDEAL: Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering

      -Trial Overview by Dr. Terje Pedersen (AHA 2005)

JUPITER: Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin

      -Trial Overview by Dr. Paul Ridker (AHA 2008)

LAPLACE-TIMI57

      -LDL-C Assessment with PCSK9 monoclonaL Antibody inhibition Combined with statin thErapy – Thrombolysis In Myocardial Infarction-57 by Dr. Robert P. Giugliano (AHA 2012)

LIPID: Long-Term Intervention With Pravastatin in Ischemic Disease Trial

      -Trial Overview

Lipid Management

      -How Aggressive Do We Get on Lipids? by Dr. Christopher P. Cannon

Long-Term Reduction in Low-Density Lipoprotein Cholesterol: A Mendelian Randomized Controlled Trial of Long-Term Reduction of LDL-C Beginning Early in Life

      -Trial Overview by Dr. Brian A. Ference (ACC 2012)

MEGA: Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese

      -Trial Overview by Dr. Haruo Nakamura (AHA 2005)

METEOR: Measuring Effects of Intima-Media Thickness: An Evaluation of Rosuvastatin

      -Trial Overview by Dr. John R. Crouse III (ACC 2007)

      -View an Animated Presentation

      -View Other Resources

PCSK9: A Randomized, Double Blind, Placebo-controlled Trial of the Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients with Primary Hypercholesterolemia

      -Trial Overview by Dr. James McKenney (ACC 2012)

 

SHARP: Study of Heart and Renal Protection

      -Trial Results by Dr. Colin Baigent and Dr. Martin Landray

PROVE IT - TIMI 22: Pravastatin Or Atorvastatin Evaluation and Infection Therapy - Thrombolysis In Myocardial Infarction 22

      -Trial Overview by Dr. Christopher Cannon

RAAVE: Rosuvastatin Affecting Aortic Valve Endothelium to Slow the Progressions of Aortic Stenosis

      -Trial Overview by Dr. Luis M. Moura (2007)

REVERSAL: Reversing Atherosclerosis with Aggressive Lipid Lowering

      -Trial Overview by Dr. Steven E. Nissen (AHA 2003)

RUTHERFORD: Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder

      -Interim Results by Dr. Frederick J. Raal (AHA 2012)

SAGE: Study Assessing Goals in the Elderly

      -Trial Overview by Dr. Prakash Deedwania (2007)

 

SATURN: Comparison of the Progression of Coronary Atherosclerosis for Two High-efficacy Statin Regimens with Different HDL Effects

      -Trial Overview by Dr. Stephen Nicholls (AHA 2011)

Simvastatin

      -Lipid-Altering Efficacy and Safety of Simvastatin 80 mg/day: Long-Term Experience in a Large Group of Patients with Hypercholesterolemia by Dr. Leiv Ose, et al.

Statin Therapy

      -The Benefit of Statin Therapy Before and After Coronary Revascularization by Dr. C. Michael Gibson

TNT: Treating to New Targets

      -Trial Overview by Dr. John C. LaRosa (ACC 2005)

WOSCOPS: West Of Scotland Coronary Prevention Study

      -Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia by Dr. James Shepherd

 

YELLOW: Reduction in Yellow Plaque by Aggressive Lipid Lowering Therapy

      -Trial Overview by Dr. Annapoorna Kini (ACC 2012)

(Return to Contents)

 HDL Raising

ASSERT: First Major Clinical Trial of an Oral Agent Inducing Apo-A-I Synthesis: A New Approach to Raising HDL and CV Risk Modification

      -Trial Results by Dr. Stephen Nicholls (AHA 2010)

 

Atherosclerosis

      -Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis by Dr. Stephen J. Nicholls, et al. (2007)

Dal-OUTCOMES: Effects of the Cholesteryl Ester Transfer Protein Inhibitor Dalcetrapib in Patients with Recent Acute Coronary Syndrome

      -Trial Overview by Dr. Gregory G. Schwartz (AHA 2012)

ERASE: Effect of rHDL on Atherosclerosis-Safety and Efficacy

      -Trial Overview by Dr. Jean-Claude Tardif (ACC 2007)

ILLUSTRATE: Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation

      -Trial Overview by Dr. Steven E. Nissen (ACC 2007)

 

SATURN: Comparison of the Progression of Coronary Atherosclerosis for Two High-efficacy Statin Regimens with Different HDL Effects

      -Trial Overview by Dr. Stephen Nicholls (AHA 2011)

Simvastatin's Impact on HDL

      -Effects of High Doses of Simvastatin and Atorvastatin on High-Density Lipoprotein Cholesterol and Apolipoprotein A-1 by Dr. John R. Crouse III, et al. (1999)

      -Simvastatin Increases HDL-C and Apolipoprotein A-1 Levels Significantly More Than Atorvastatin by Dr. John P. Kastelein et al. (ACC 2000)

VA-HIT: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial

      -Trial Overview

(Return to Contents)

 Other Lipid Lowering

ACTIVATE: Acyl-coenzyme A: Cholesterol Acyltransferase (ACAT) Inhibition on the Progression of Coronary Atherosclerosis

      -Simvastatin vs Placebo for Mortality in Coronary Heart Disease by Dr. Steven E. Nissen (AHA 2005)

BIP: Bezafibrate Infarction Prevention

      -Trial Results (European Society of Cardiology Meeting, 1998)

OmniHeart Feeding Study

      -DASH Diet vs DASH with Higher Protein Content by Dr. Lawrence J. Appel (AHA 2005)

SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine

      -Trial Overview by Dr. Rory Collins and Dr. Jane Armitage (AHA 2008)

Vytorin

      -Postmarket Statin Analysis of Vytorin and Cancer by Dr. Alawi A. Alsheikh-Ali and Dr. Richard H. Karas

(Return to Contents)

 Obesity

RIO EUROPE: A Randomised Double-Blind Study of Weight Reducing Effect and Safety of Rimonabant in Obese Patients With or Without Comorbidities

      -Trial Overview by Dr. Luc Van Gaal (ACC 2005)

RIO LIPIDS: Rimonabant in Obesity

      -Trial Overview by Dr. Jean-Pierre Despres (ACC 2004)

(Return to Contents)

 Smoking Cessation

STRATUS-US: Smoking Cessation in Smokers Motivated to Quit

      -Trial Overview by Dr. Robert Anthenelli (ACC 2004)

(Return to Contents)

 Vitamins

NORVIT: Norwegian Vitamin Trial

      -Trial Overview by Dr. Kaare Harold Bønaa (European Society of Cardiology Congress 2005)

Physicians' Health Study II: Multivitamins in the Prevention of Cardiovascular Disease in Men

    -Trial Overview by Dr. Howard D. Sesso et al. (AHA 2012)

 

WENBIT Trial: Western Norway B-vitamin Intervention Trial

      -Trial Overview by Dr. Marta Ebbing (European Society of Cardiology Congress 2007)

Women's Health Study

      -Vitamine E in Primary Prevention by Dr. Julie E. Buring (ACC 2005)

(Return to Contents)

Who Are We?    Slide Downloading Policy   Financial Disclosure    We Do Not Promote Off Label Product Use    Copyright    Source of Slides    Editorial Policy    Links Policy    Privacy Policy   Access    CME Programs

© 1999-2009 by Clinical Trial Results .org.  None of the materials on this website may be reproduced, modified, distributed, transmitted, republished, displayed, or performed unless prior written approval is obtained by Clinical Trial Results.  All such requests should be forwarded to Susan J. Marble at smarble@clinicaltrialresults.org. For further information please see the Policy section. Webmaster